The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of the body, shipped to a specialized facility, genetically reprogrammed, ...
For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results